COVID-19 Vaccine: The United States has expressed confidence in the Remedisivier drug for the treatment of COVID-19 disease, saying there has been "clear" evidence that the medicine can cure COVID-19 patients.
It has been revealed in the clinical trial of this medicine that the symptoms start appearing in patients within 11 days instead of 15 days.
However, so far, no complete information has been revealed about the investigation conducted on this drug.
But experts say that if the claims related to this drug are confirmed, then there will be great news of the current era.
But he has also said that this medicine is not like the magic bud for this disease.
This drug will develop the ability to save lives, reduce the burden on hospitals, and remove lockdowns in some places.
COVID-19 Vaccine: remdesivir hopes raised in the battle against Corona Virus
Where did this medicine come from?
COVID-19 Vaccine: This drug was originally developed to treat Ebola. It is an antiviral drug.
When any virus enters the human body, it replicates itself to make itself stronger, to make itself stronger.
And it happens in the cells of the human body. But in this process, the virus needs an enzyme.
By attacking this enzyme, this drug forms a barrier in the path of the virus.
In the United States, this drug has been tried at the National Institute of Allergy and Infectious Diseases of America.
One thousand sixty-three people participated in this trial. Some of these patients were given this drug.
In the world of medicines, placebo means something that does not have any medical properties.
These may include things like water and sugar tablets.
How successful is this medicine?
COVID-19 Vaccine: Dr. Anthony Fauchi, head of the US National Institute of Allergy and Infectious Diseases, has said that the trial data shows that this drug is proving effective in curing patients suffering from COVID-19.
They have said that the drug can block the virus, and it was indicating that we will now have a way that we can treat the patients.
However, this drug has no apparent effect on deaths from COVID-19.
Among those who were given this medicine, the mortality rate was 8 percent.
At the same time, those who were given a placebo, it was 11.6 percent. But these results are not important from a statistical basis.
This means that scientists are not able to tell whether the difference in mortality is accurate or not.
It is also not clear who is benefiting.
Is it helping those who recover more quickly, who would have been cured even without medication?
- In which age groups does the medicine work better or less?
- Is this disease protecting people from going to ICU?
- Does this medicine work better with the young and old?
- Or which of these drugs affects sick or healthy people?
- Do patients need to be cared for at the initial stage when the virus is at its peak?
COVID-19 Vaccine: When detailed information related to this medicine will be released, then the answers to such special questions will be revealed.
Because this drug can have benefits such as the removal of lockdown along with saving people's lives.
Professor Mahesh Parmar, director of the MRC Clinical Trial Unit at UCL College, London, says, "Many things need to be clarified before this drug becomes widely available.
The data and results related to it need to be reviewed by regulators so that The drug can be licensed.
Along with this, the assessment from the health departments of different countries will also be necessary. "
"When all this is happening, then we will get more and long-term data from this trial and other trials, to determine whether this drug also prevents COVID-19 or not.
If medicine can prevent people from going to the ICU, then the risk of us being overworked at hospitals is reduced.
What will be the benefit?
With this, the need for social distancing can be reduced.
Professor Peter Horby of Oxford University is currently campaigning to find the drug of COVID-19 on a much wider scale.
"We need to see the full results. But if the claims made about this drug are confirmed, then it will be very good, and it will be a piece of very good news in the ongoing war against COVID-19," Horby has said.
"After this, the next few steps include sharing the information related to it and making this medicine available to all."
When this information about this medicine has come out from the US, then the report of the trial conducted on this medicine in China has been published in Lancet Medical Journal, according to which this drug has proved to be ineffective.
However, this trial in China was incomplete, as the number of patients in China was reduced due to the success of the lockdown.
Professor Babak Javid, an expert on infectious diseases at Cambridge University, says, "These figures are much better.
But with no drugs available for COVID-19, this drug can be approved soon.
But these results also suggest that Remedies are not a magic wand. In such a situation, the total benefit of recovering people is 30 percent.
Along with this, other drugs that are undergoing testing for COVID-19 include medicines used for malaria and HIV.
These drugs contain compounds that attack immunity and relax immunity.
However, antiviral drugs are used in the early stages and in the later stages of the disease.